聚乳酸载药纳米球的制备工艺及性能研究

南方医科大学学报 ›› 2004, Vol. 24 ›› Issue (03): 352-354.

聚乳酸载药纳米球的制备工艺及性能研究

李良¹, 李国明², 黄伟华¹

1. 南昌市卫生防疫站, 江西, 南昌, 330006;
2. 华南师范大学化学系, 广东, 广州, 510631

出版日期:2004-03-20 发布日期:2004-03-20
基金资助:
收稿日期:2003-7-23。
作者简介:李良(1975- ),男,硕士,技师,研究方向:生物医学高分子药物缓释材料,E-mail:liangli113@sina.com

Preparation of drug-loaded polylactic acid nanospheres and drug-releasing performance evaluation

LI Liang¹, LI Guo-ming², HUANG Wei-hua¹

1. 南昌市卫生防疫站, 江西, 南昌, 330006;
2. 华南师范大学化学系, 广东, 广州, 510631

Online:2004-03-20 Published:2004-03-20

摘要/Abstract

摘要： 运用均匀设计实验,以灰黄霉素为囊心物质用油包水溶剂挥发法制备灰黄霉素/聚乳酸纳米球,并且分析比较了载药微米球和纳米球的释药性能。结果表明所获得的纳米球球形较好且较为分散,粒径分布较为均一,粒径在114 nm左右。经线性回归和三次重复试验得出综合评分S为95.59,误差为3.66%,载药量为13.55%。载药微米球的释药速率较慢,而纳米球在性能上有一个“突跃”,能起到“增溶”药物的作用。

Abstract: The polylactic acid (PLA) nanospheres containing griseofulvin were prepared by a water-in-oil solvent evaporation method adopting an uniformly designed experiment, and the drug-releasing rates were compared between the microsphere and nanosphere. The results showed that the nanospheres was good in spherical shape with narrow distribution of the particle sizes. The particle diameter was about 114 nm, and the comprehensive score of the nanosphere was 95.59, with the error of 3.66% and the drug content of 13.55% by the linearity regression averaged from the results of the three repeat experiments. The drug-releasing rate of the microsphere was relatively slow, while that of the nanosphere can have an abrupt increase, indicating its function of solubilizing the drug.

中图分类号:

O636
TQ467

李良¹, 李国明², 黄伟华¹. 聚乳酸载药纳米球的制备工艺及性能研究[J]. 南方医科大学学报, 2004, 24(03): 352-354.

LI Liang¹, LI Guo-ming², HUANG Wei-hua¹. Preparation of drug-loaded polylactic acid nanospheres and drug-releasing performance evaluation[J]. Journal of Southern Medical University, 2004, 24(03): 352-354.

参考文献

[1] Yoo HS, Lee KH, Oh JE, et al. in vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates[J]. J Control Rel, 2000, 68(3): 419-26.
[2] Torres EC, Rodrigues JM, Moreira DL, et al. Improvement of in vitro and in vivo antileishmanial activities of 2’, 6’-dihydroxy-4’ -methoxychalcone by entrapment in poly(D, L-lactide)nanoparticles[J]. Antimicrob Agents Chemother, 1999, 43(7): 1776-82.
[3] Sershen SR, Westcott SL, Halas NJ, et al. Temperature-sensitive Polymer nanoshell composites for photothermally modulated drug delivery[J]. J Biomed Mater Res, 2000, 51(3): 293-300.
[4] Roy K, Mao HQ, Huang SK, et al. Oral gene delivery with chitosan DNA nanoparticles generates immunologic protection in a murine model of peanut allergy[J]. Nat Med, 1999, 5(4): 387-95.
[5] Schwarz C, Mehnert W. Solid liquid nanoparticles(SLN) for control led-drug delivery Ⅱ. Drug incorpouation and physicochemical chara cterization[J]. J Microencapsul, 1999, 16(2): 205-13.
[6] Duchene D, Ponchel G, Denis W. Cyclodextrins in targeting appli cation to nanoparticles [J]. Adv Drug Delve Rev, 1999, 36(3): 29-40.
[7] Song CX, Labhasetwar V, Murohy H, et al. Formulation and charac terization of biodegradable nanoparticles for intravascular local drug delivery[J]. J Control Release, 1997, 43(5): 197-212.
[8] Niwa T, Takeuchi H, Hino T, et al. Biodegradable subicron carries for peptide drugs: preparation ofDL-PLGA nanoparticles with Naby a novel emulsion-phase separation method in an oil system [J]. Int F Pharm, 1995, 121(1): 45-53.
[9] 常津,刘海峰,姚康德.医用纳米控释系统的研究进展[J].中国生物医学工程学报(Chin JBiomedEng),2000,19(4):423-31.
[10] 黎洪珊,赵京玲,魏树礼.环孢菌素A聚乳酸纳米粒胶体的制备和大鼠的口服吸收[J].中国药学杂志(Chin Pharm J),1999,34(8):532-6.
[11] 皮洪琼,吴俊丽,袁直,等.注射用生物可降解胰岛素纳米球的制备[J].应用化学,2001,18(5):365-9.
[12] 中华人民共和国卫生部药典委员会编.药典注释[M].北京:化学工业出版社,1990.209-11.